News
Macomics Voted as Winner of One Nucleus BioNewsRound Award 2023 for Translational Research
Press release
Edinburgh and Cambridge, UK, 7 July 2023 - Macomics…
In Memoriam Jeffrey William Pollard – Macomics’ founder, director and advisor
It is with great sadness that we announce the passing of our esteemed colleague and friend, Professor Jeff W. Pollard, on 1 May 2023.
Macomics Presents its ENIGMAC™ Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR
Macomics Ltd, a leader in macrophage drug discovery has presented data demonstrating the power of its ENIGMAC™ macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting, AACR 2023, April 14-19, Florida.
Macomics and Ono Pharmaceutical partner to discover and develop macrophage-targeting antibody therapy
Macomics Ltd, a leader in macrophage drug discovery, announces…
Mapping out the discoveries of a new class of tumour-associated immune cells
Scientists at Macomics and University of Edinburgh map out the discoveries of a new class of tumour-associated immune cells revealing opportunities to develop novel cancer treatments
Macomics’ co-founder Professor Jeffrey Pollard celebrated in Highly Cited Researchers 2022
Macomics Ltd, biotech company with world-leading expertise in macrophage biology, is proud to announce that its co-founder Prof. Jeffery Pollard PhD has been honoured with a place in Clarivate’s annual Highly Cited Researchers 2022 list for the second year running.
Professor Jeffrey Pollard Macomics’ Co-founding Board Member and Chair of its SAB Elected to the Academia Europaea
Prof. Pollard will be welcomed as a new at a ceremony during the 33rd Annual Conference of Academia Europaea, Building Bridges 2022, in Barcelona 27-27 October.
Macomics announces the appointment of Roche Executive, Dr Valérie Méresse Naegelen
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen, Global Head of Translational Sciences Oncology at the Pharma Division of Roche has joined its panel of Clinical Advisors.
Macomics to present at upcoming conferences in September and October
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.
Macomics announces new hires as it expands its macrophage-based drug discovery and operations teams
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made three new appointments to its scientific and operations teams, to support growth and accelerate its R&D.
Macomics to present at upcoming conferences
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.
Macomics brings on five additional advisors with internationally renowned immunology and clinical oncology expertise
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has added five new internationally renowned Advisors to expand the immunology, oncology and clinical expertise within its advisory panel.
Macomics’ Co-founder Professor Jeffrey Pollard honoured in Highly Cited Researchers 2021
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is proud to announce that its co-founder Prof. Jeffery Pollard PhD has been named on the annual Highly Cited Researchers 2021 list from Clarivate.
Macomics’ co-founder Dr Luca Cassetta honoured with Society for Immunotherapy of Cancer Award for Publication
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that its co-founder and Vice President Immunology, Dr Luca Cassetta has been honoured by the Society for Immunotherapy of Cancer.
Macomics announces new hires that expands its macrophage-based drug discovery R&D Team
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made five new appointments to its scientific team, to support and accelerate its R&D.
Macomics secures £4.24 million expansion financing
Macomics Limited, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m.
Dr. Krzystof Wicher, to Chair sessions at the European Drug Discovery Strategic Summit
Macomics is pleased to announce that Dr. Krzystof Wicher, VP of Drug Discovery, will Chair sessions on Target Identification and Validation and Drug Design Strategies at the European Drug Discovery Strategic Summit.
Macomics appoints leading cancer immunologists to its advisory panel
Macomics has expanded its advisory team with the appointment of Prof. Michele De Palma and Dr. Jackie Doody, internationally renowned experts in the fields of immuno-oncology.
Macomics welcomes Founder, Prof. Jeffrey W. Pollard’s review article in leading journal Immunity
In a special edition of Immunity, focussed on the tumour immune microenvironment, Prof Pollard and Dr. Esra Güç publish an article entitled Redefining macrophage and neutrophil biology in the metastatic cascade.
Macomics Senior Scientist, Dr. Martha Lopez-Yrigoyen to Chair sessions at 2021 Tumour myeloid Microenvironment Directed Therapeutics Summit
Macomics is pleased to announce that Dr Lopez-Yrigoyen will Chair sessions at 2021 Tumour myeloid Microenvironment Directed Therapeutics Summit.
Macomics secures £3.2 million seed funding
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, launches today with a £3.2 million seed financing round led by transatlantic VC Epidarex Capital, with the Scottish Investment Bank, the investment arm of Scottish Enterprise, also investing.